Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Substance Abuse Treatment, Prevention, and Policy
Published in: Substance Abuse Treatment, Prevention, and Policy 1/2018

Open Access 01-12-2018 | Research

An age-based analysis of nonmedical prescription opioid use among people who use illegal drugs in Vancouver, Canada

Authors: Tessa Cheng, Will Small, Huiru Dong, Ekaterina Nosova, Kanna Hayashi, Kora DeBeck

Published in: Substance Abuse Treatment, Prevention, and Policy | Issue 1/2018

Login to get access

Abstract

Background

Nonmedical prescription opioid use (NMPOU) is a serious public health problem in North America. At a population-level, previous research has identified differences in the prevalence and correlates of NMPOU among younger versus older age groups; however, less is known about age-related differences in NMPOU among people who use illegal drugs.

Methods

Data were collected between 2013 and 2015 from two linked prospective cohort studies in Vancouver, Canada: the At-Risk Youth Study (ARYS) and the Vancouver Injection Drug Users Study (VIDUS). Factors independently associated with NMPOU among younger (ARYS) and older (VIDUS) participants were examined separately using bivariate and multivariate generalized estimating equations.

Results

A total of 1162 participants were included. Among 405 eligible younger participants (Median age = 25; Inter-Quartile Range [IQR]: 22–28), 40% (n = 160) reported engaging in NMPOU at baseline; among 757 older participants (Median age = 48, IQR: 40–55), 35% (n = 262) reported engaging in NMPOU at baseline. In separate multivariate analyses of younger and older participants, NMPOU was positively and independently associated with heroin use (younger: Adjusted Odds Ratio [AOR] = 3.12, 95% Confidence Interval [CI]: 2.08–4.68; older: AOR = 2.79, 95% CI: 2.08–3.74), drug dealing (younger: AOR = 2.22, 95% CI: 1.58–3.13; older: AOR = 1.87, 95% CI: 1.40–2.49), and difficulty accessing services (younger: AOR = 1.47, 95% CI: 1.04–2.09; older: AOR = 1.74, 95% CI: 1.32–2.29). Among the youth cohort only, NMPOU was associated with younger age (AOR = 1.12, 95% CI: 1.05–1.19), crack use (AOR = 1.56, 95% CI: 1.06–2.30), and binge drug use (AOR = 1.41, 95% CI: 1.00–1.97); older participants who engaged in NMPOU were more likely to report crystal methamphetamine use (AOR = 1.97, 95% CI: 1.46–2.66), non-fatal overdose (AOR = 1.76, 95% CI: 1.20–2.60) and sex work (AOR = 1.49, 95% CI: 1.00–2.22).

Discussion

The prevalence of NMPOU is similar among younger and older people who use drugs, and independently associated with markers of vulnerability among both age groups. Adults who engage in NMPOU are at risk for non-fatal overdose, which highlights the need for youth and adult-specific strategies to address NMPOU that include better access to health and social services, as well as a range of addiction treatment options for opioid use. Findings also underscore the importance of improving pain treatment strategies tailored for PWUD.
Literature
1.
Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52.PubMedCrossRef
2.
Nolan S, Socias ME, Wood E. The Threat of an International Opioid Crisis. Current Addiction Reports; 2018.
3.
Meier EA, Troost JP, Anthony JC. Extramedical use of prescription pain relievers by youth aged 12 to 21 years in the United States: national estimates by age and by year. Arch Pediatr Adolesc Med. 2012;166(9):803–7.PubMedPubMedCentralCrossRef
4.
Miech R, Bohnert A, Heard K, Boardman J. Increasing use of nonmedical analgesics among younger cohorts in the United States: a birth cohort effect. J Adolesc Health. 2013;52(1):35–41.PubMedCrossRef
5.
Fischer B, Ialomiteanu A, Kurdyak P, Mann RE, Rehm J. Reductions in non-medical prescription opioid use among adults in Ontario, Canada: are recent policy interventions working? Subst/ Abus Treatment Prev Pol. 2013;8:4.CrossRef
6.
Currie CL, Wild TC. Adolescent use of prescription drugs to get high in Canada. Can J Psychiatry. 2012;57(12):745–51.PubMedCrossRef
7.
Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based study. J Am Acad Child Adolesc Psychiatr. 2008;47(7):745–54.
8.
Veliz PT, Boyd C, McCabe SE. Playing through pain: sports participation and nonmedical use of opioid medications among adolescents. Am J Public Health. 2013;103(5):e28–30.PubMedPubMedCentralCrossRef
9.
10.
Back SE, Payne RL, Simpson AN, Brady KT. Gender and prescription opioids: findings from the National Survey on drug use and health. Addict Behav. 2010;35(11):1001–7.PubMedPubMedCentralCrossRef
11.
Shield KD, Ialomiteanu A, Fischer B, Mann RE, Rehm J. Non-medical use of prescription opioids among Ontario adults: data from the 2008/2009 CAMH Monitor. Can J Public Health = Revue canadienne de sante publique. 2011;102(5):330–5.PubMed
12.
Martins SS, Keyes KM, Storr CL, Zhu H, Grucza RA. Birth-cohort trends in lifetime and past-year prescription opioid-use disorder resulting from nonmedical use: results from two national surveys. J Stud Alcohol Drugs. 2010;71(4):480–7.PubMedPubMedCentralCrossRef
13.
Suryaprasad AG, White JZ, Xu FJ, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411–9.PubMedCrossRef
14.
Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36(8):829–34.PubMedPubMedCentralCrossRef
15.
Osgood ED, Eaton TA, Trudeau JJ, Katz NP. A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools. Am J Drug Alcohol Abuse. 2012;38(2):166–70.PubMedCrossRef
16.
Cerdá M, Santaella J, Marshall BDL, Kim JH, Martins SS. Nonmedical Prescription Opioid Use in Childhood and Early Adolescence Predicts Transitions to Heroin Use in Young Adulthood: A National Study. J Pediatr. 2015;167(3):605–12.e1 2.PubMedPubMedCentralCrossRef
17.
Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37–44.PubMedCrossRef
18.
Lawson KM, Back SE, Hartwell KJ, Maria MMS, Brady KT. A comparison of trauma profiles among individuals with prescription opioid, nicotine, or cocaine dependence. Am J Addict. 2013;22(2):127–31.PubMedPubMedCentralCrossRef
19.
Caviness CM, Anderson BJ, de Dios MA, Kurth M, Stein M. Prescription medication exchange patterns among methadone maintenance patients. Drug Alcohol Depend. 2013;127(1–3):232–8.PubMedCrossRef
20.
Arnett JJ. Emerging adulthood: what is it, and what is it good for? Child Dev Perspect. 2007;1(2):68–73.CrossRef
21.
Degenhardt L, Stockings E, Patton G, Hall WD, Lynskey M. The increasing global health priority of substance use in young people. The Lancet Psychiatry. 2016;3(3):251–64.PubMedCrossRef
22.
Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, et al. Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the United States. J Clin Psychiatry. 2016;77(6):772–80.PubMedPubMedCentralCrossRef
23.
24.
Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in u.s. adults: 2015 national survey on drug use and health. Ann Intern Med. 2017;167(5):293–301.PubMedCrossRef
25.
Lake S, Milloy MJ, Dong H, Hayashi K, Wood E, Kerr T, et al. Initiation into prescription opioid injection and associated trends in heroin use among people who use illicit drugs. Drug Alcohol Depend. 2016;169:73–9.PubMedPubMedCentralCrossRef
26.
Voon P, Callon C, Nguyen P, Dobrer S, Montaner JS, Wood E, et al. Denial of prescription analgesia among people who inject drugs in a Canadian setting. Drug Alcohol Rev. 2015;34(2):221–8.PubMedCrossRef
27.
Voon P, Callon C, Nguyen P, Dobrer S, Montaner J, Wood E, et al. Self-management of pain among people who inject drugs in Vancouver. Pain Manag. 2014;4(1):27–35.PubMedCrossRef
28.
DeBeck K, Wood E, Dong H, Dobrer S, Hayashi K, Montaner J, et al. Non-medical prescription opioid use predicts injection initiation among street-involved youth. Int J Drug Policy. 2016;34:96–100.PubMedPubMedCentralCrossRef
29.
Silva K, Schrager SM, Kecojevic A, Lankenau SE. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. Drug Alcohol Depend. 2013;128(1–2):104–10.PubMedCrossRef
30.
Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug And Alcohol Rev. 2008;27(6):625–32.CrossRef
31.
Havens JR, Lofwall MR, Frost SDW, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44–52.PubMedPubMedCentralCrossRef
32.
Gwin Mitchell S, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhf A, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346–55.PubMedCrossRef
33.
Young AM, Havens JR, Leukefeld CG. A comparison of rural and urban nonmedical prescription opioid users’ lifetime and recent drug use. Am J Drug and Alcohol Abuse. 2012;38(3):220–7.CrossRef
34.
Pollini RA, Banta-Green CJ, Cuevas-Mota J, Metzner M, Teshale E, Garfein RS. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abus Rehabil. 2011;2:173–80.CrossRef
35.
Rhodes T, Lilly R, Fernandez C, Giorgino E, Kemmesis UE, Ossebaard HC, et al. Risk factors associated with drug use: the importance of ‘risk environment’. Drug-Educ Prev Polic. 2003;10(4):303–29.CrossRef
36.
Wood E, Stoltz J-A, Montaner J, Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J. 2006;3(1):18.PubMedPubMedCentralCrossRef
37.
Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–65.PubMedCrossRef
38.
Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods. 2004;7(2):127–50.CrossRef
39.
Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364–75.PubMedCrossRef
40.
Ferguson KM, Bender K, Thompson SJ, Maccio EM, Pollio D. Employment status and income generation among homeless young adults. Youth Soc. 2011;44(3):385–407.CrossRef
41.
Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57(1):120–5.PubMedCrossRef
42.
Hin L-Y, Wang Y-G. Working-correlation-structure identification in generalized estimating equations. Stat Med. 2008;28(4):642–58.CrossRef
43.
Fischer B, Ialomiteanu A, Boak A, Adlaf E, Rehm J, Mann RE. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug And Alcohol Rev. 2013;32(3):276–87.CrossRef
44.
Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD: (Office of Applied Studies - NSDUH Series H-38A, HHS Publication No. SMA 10–4586 Findings); 2010.
45.
Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821–6.PubMedCrossRef
46.
Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46(Supplement C):172–9.PubMedPubMedCentralCrossRef
47.
Lysyshyn M, Dohoo C, Forsting S, Kerr T, McNiel R, editors. Evaluation of a fentanyl drug checking program for clients of a supervised injection site, Vancouver, Canada. Montreal: Harm reduction international; 2017.
48.
British Columbia Coroners Service. Fentanyl-detected illicit drug overdose deaths January 1, 2012 to august 31, 2017. Burnaby, BC: Ministry of Public Safety and Solicitor General; 2017.
49.
50.
Centers for Disease Control and Prevention. Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities [press release]. Atlanta: Office of Public Health Preparedness and Response; 2015.
51.
Fischer B, Vojtila L, Rehm J. The ‘fentanyl epidemic’ in Canada – some cautionary observations focusing on opioid-related mortality. Prev Med. 2018;107:109–13.PubMedCrossRef
52.
British Columbia Centre on Substance Use and B.C. Ministry of Health. Vancouver: A Guideline for the Clinical Management of Opioid Use Disorder; 2017.
53.
Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA psychiatry. 2016;73(5):447–55.PubMedCrossRef
54.
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. New Engl J Med. 2009;361(8):777–86.PubMedCrossRef
55.
56.
Thomson E, Lampkin H, Maynard R, Karamouzian M, Jozaghi E. The lessons learned from the fentanyl overdose crises in British Columbia, Canada. Addiction. 2017;112(11):2068–70.PubMedCrossRef
57.
Jozaghi E, Greer AM, Lampkin H, Buxton JA. Activism and scientific research: 20 years of community action by the Vancouver area network of drug users. Subst Abuse Treat Prev Policy. 2018;13(1):18.PubMedPubMedCentralCrossRef
58.
Jozaghi E, Marsh S. Missing the trends in the fentanyl overdose crisis: The need for immediate intervention in small and rural communities. Can J Public Health = Revue canadienne de sante publique. 2017;108(4):e457.PubMedCrossRef
59.
Boyd S, Association NP. Yet they failed to do so: recommendations based on the experiences of NAOMI research survivors and a call for action. Harm Reduct J. 2013;10(1):6.PubMedPubMedCentralCrossRef
60.
Boyd S, Murray D, Snap, MacPherson D. Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver. Harm Reduct J. 2017;14:27.PubMedPubMedCentralCrossRef
61.
McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, et al. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: a qualitative study. Soc Sci Med. 2015;133:168–76.PubMedPubMedCentralCrossRef
62.
Woo A. The quiet rise of crystal meth. The Globe and Mail; 2016.
63.
Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015;12(1):54.PubMedPubMedCentralCrossRef
64.
Merali F. ‘The elephant in the room’: crystal meth use in Vancouver rises 600% over last decade. CBC News; 2017.
65.
Werb D, Kerr T, Buxton J, Shoveller J, Richardson C, Montaner J, et al. Crystal methamphetamine and initiation of injection drug use among street-involved youth in a Canadian setting. CMAJ : Canadian Medical Association Journal. 2013;185(18):1569–75.PubMedCrossRefPubMedCentral
66.
Rudd RA, Aleshire N, Zibbell JE, Matthew GR. Increases in drug and opioid overdose deaths—United States, 2000–2014. Am J Transplant. 2016;16(4):1323–7.CrossRef
67.
Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain medicine (Malden, Mass). 2012;13(1):87–95.CrossRef
68.
Brothers S. Merchants, samaritans, and public health workers: secondary syringe exchanger discursive practices. Int J Drug Policy. 2016;37:1–8.PubMedCrossRef
69.
Bouchard M, Hashimi S, Tsai K, Lampkin H, Jozaghi E. Back to the core: a network approach to bolster harm reduction among persons who inject drugs. Int J Drug Policy. 2018;51:95–104.PubMedCrossRef
70.
Krüsi A, Fast D, Small W, Wood E, Kerr T. Social and structural barriers to housing among street-involved youth who use illicit drugs. Health Soc Care community. 2010;18(3):282–8.PubMedPubMedCentral
71.
Small W, Shoveller J, Moore D, Tyndall M, Wood E, Kerr T. Injection drug users’ access to a supervised injection facility in Vancouver, Canada: the influence of operating policies and local drug culture. Qual Health Res. 2011;21(6):743–56.PubMedCrossRef
72.
McNeil R, Cooper H, Small W, Kerr T. Area restrictions, risk, harm, and health care access among people who use drugs in Vancouver, Canada: a spatially oriented qualitative study. Health Place. 2015;35:70–8.PubMedPubMedCentralCrossRef
73.
Krug A, Hildebrand M, Sun N. “We don’t need services. We have no problems”: exploring the experiences of young people who inject drugs in accessing harm reduction services. J Int AIDS Soc. 2015;18:19442 (1758–2652 (Electronic)).PubMedPubMedCentralCrossRef
74.
Merkinaite S, Grund JP, Frimpong A. Young people and drugs: next generation of harm reduction. Int J Drug Policy. 2010;21(2):112–4.PubMedCrossRef
75.
Frank D, Mateu-Gelabert P, Guarino H, Bennett A, Wendel T, Jessell L, et al. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. 2015(1873–4758 (Electronic)).
76.
Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318–27.PubMedCrossRef
77.
Floyd LJ, Alexandre PK, Hedden SL, Lawson AL, Latimer WW, Giles N. Adolescent drug dealing and race/ethnicity: a population-based study of the differential impact of substance use on involvement in drug trade. Am J Drug and Alcohol Abuse. 2010;36(2):87–91.CrossRef
78.
Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolesc Health. 2005;37(1):44–51.PubMedCrossRef
79.
DeBeck K, Shannon K, Wood E, Li K, Montaner J, Kerr T. Income generating activities of people who inject drugs. Drug Alcohol Depend. 2007;91(1):50–6.PubMedPubMedCentralCrossRef
80.
Werb D, Kerr T, Li K, Montaner J, Wood E. Risks surrounding drug trade involvement among street-involved youth. Am J Drug Alcohol Ab. 2008;34(6):810–20.CrossRef
81.
Deering KN, Shoveller J, Tyndall MW, Montaner JS, Shannon K. The street cost of drugs and drug use patterns: relationships with sex work income in an urban Canadian setting. Drug Alcohol Depend. 2011;118(2–3):430–6.PubMedPubMedCentralCrossRef
82.
83.
Ochnio JJ, Patrick D, Ho M, Talling DN, Dobson SR. Past infection with hepatitis a virus among Vancouver street youth, injection drug users and men who have sex with men: implications for vaccination programs. Can Med Assoc J. 2001;165(3):293–7.
84.
Miller CL, Strathdee SA, Kerr T, Li K, Wood E. Factors associated with early adolescent initiation into injection drug use: implications for intervention programs. J Adolesc Health. 2006;38(4):462–4.PubMedCrossRef
85.
Cheng T, Wood E, Feng C, Mathias S, Montaner J, Kerr T, et al. Transitions into and out of homelessness among street-involved youth in a Canadian setting. Health Place. 2013;23:122–7.PubMedPubMedCentralCrossRef
86.
Werb D, Kerr T, Buxton J, Shoveller J, Richardson C, Montaner J, et al. Patterns of injection drug use cessation during an expansion of syringe exchange services in a Canadian setting. Drug Alcohol Depend. 2013;132(3):535–40.PubMedPubMedCentralCrossRef
87.
DeBeck K, Kerr T, Li K, Milloy MJ, Montaner J, Wood E. Incarceration and drug use patterns among a cohort of injection drug users. Addiction. 2008;104(1):69–76.CrossRef
88.
Marshall BDL, Wood E, Shoveller JA, Patterson TL, Montaner JSG, Kerr T. Pathways to HIV risk and vulnerability among lesbian, gay, bisexual, and transgendered methamphetamine users: a multi-cohort gender-based analysis. BMC Public Health. 2011;11(1):20.PubMedPubMedCentralCrossRef
89.
Ti L, Socías ME, Wood E, Milloy MJ, Nosova E, DeBeck K, et al. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLoS One. 2018;13(3):e0194162.PubMedPubMedCentralCrossRef
90.
Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12):2053–9.PubMedPubMedCentralCrossRef
91.
Hunt DE, Kling R, Almozlino Y, Jalbert S, Chapman MT, Rhodes W. Telling the truth about drug use: how much does it matter? J Drug Issues. 2015;45(3):314–29.CrossRef
92.
Harris B, Shaw B, Lawson H, Sherman B. Barriers to addressing adolescent substance use: perceptions of New York school-based health center providers. J Sch Health. 2016;86(2):96–104.PubMedCrossRef
93.
Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–63.PubMedCrossRef
94.
Jozaghi E, Buxton JA, Thomson E, Marsh S, Gregg D, Bouchard M. Building new approaches to risk reduction with social networks and people who smoke illegal drugs from participatory community-based research. Int J Qual Methods. 2018;17(1):1609406918771247.CrossRef
95.
Damon W, Callon C, Wiebe L, Small W, Kerr T, McNeil R. Community-based participatory research in a heavily researched inner city neighbourhood: perspectives of people who use drugs on their experiences as peer researchers. Soc Sci Med. 2017;176:85–92.PubMedPubMedCentralCrossRef
96.
Jozaghi E, Dadakhah-Chimeh Z. A call for action to combat the growing synthetic opioid epidemic: the need for the creation and expansion of addiction and psychiatric nursing programs. J Sch Nurs. 2017;34(1):11–3.PubMedCrossRef
97.
Werb D, Buxton J, Shoveller J, Richardson C, Rowell G, Wood E. Interventions to prevent the initiation of injection drug use: a systematic review. Drug Alcohol Depend. 2013;133(2):669–76.PubMedCrossRef
Metadata
Title
An age-based analysis of nonmedical prescription opioid use among people who use illegal drugs in Vancouver, Canada
Authors
Tessa Cheng
Will Small
Huiru Dong
Ekaterina Nosova
Kanna Hayashi
Kora DeBeck
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Substance Abuse Treatment, Prevention, and Policy / Issue 1/2018
Electronic ISSN: 1747-597X
DOI
https://doi.org/10.1186/s13011-018-0180-3

Other articles of this Issue 1/2018

Substance Abuse Treatment, Prevention, and Policy 1/2018 Go to the issue

Short report

Change and variability in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993–2007

Research

A comparative analysis of pharmacists’ perspectives on codeine use and misuse – a three country survey

Research

Risk and protective factors for substance use among Iranian university students: a national study

Research

Smoking, alcohol consumption, and illicit substances use among adolescents in Poland

Research

Adolescents, parents and teachers’ perceptions of risk and protective factors of substance use in Moroccan adolescents: a qualitative study

Research

How broad are state physician health program descriptions of physician impairment?